What Alebund Pharmaceuticals does

Alebund Pharmaceuticals (礼邦医药集团) is a Shanghai-based clinical-stage biopharmaceutical company founded in 2018, developing innovative therapies for chronic kidney disease (CKD) and related complications. The company targets the full spectrum of CKD, addressing disease progression in early-to-mid stage patients (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD) and complications of end-stage renal disease (hyperphosphatemia, renal anemia). Its portfolio comprises eight products across six renal indications, with one commercialized product (Mircera for renal anemia, included in China's National Reimbursement Drug List) and three in clinical stage. The most advanced proprietary candidates are AP301, a novel fiber-iron-based oral phosphate binder that completed global Phase III enrollment in May 2026 with pivotal data demonstrating 66.7% serum phosphate target attainment versus 58.6% for sevelamer carbonate, and AP306 (EOS789), a first-in-class pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) licensed to R1 Therapeutics for global development outside Greater China in March 2026.

The company operates an integrated platform spanning R&D, manufacturing, and commercialization. Manufacturing is anchored by a self-built Yangzhou GMP facility with 200 metric tons/year API capacity for AP301, integrating API through finished dosage production at a single site with expansion space reserved for additional pipeline products. Distribution is executed through an in-house commercial team covering major Chinese cities and hundreds of hospitals, established via the Mircera NRDL launch. The company pursues global clinical development with multi-regional trials (U.S. and China) for late-stage assets and holds four breakthrough therapy or orphan drug designations (including NMPA Breakthrough Therapy Designation for AP306 and FDA Orphan Drug Designation for AP303).

Alebund monetizes through three streams: pharmaceutical product sales (Mircera via NRDL channels), licensing and milestone payments (notably the AP306/R1 Therapeutics deal with potential low triple-digit millions USD in milestones plus tiered low-double-digit royalties and equity participation), and future product revenue from AP301 upon China NDA submission and AP306 upon regional approvals. The company was incubated by leading nephrology industry experts and listed on the Hong Kong Stock Exchange in June 2026 (ticker 09637.HK), raising HK$1.28 billion (~$164 million). Notable investors include Quan Capital, Lilly Asia Ventures, Octagon Capital, Loyal Valley Capital, and GIC.

Name

Alebund Pharmaceuticals

Legal name

礼邦医药（江苏）股份有限公司

Website

https://alebund.com

Company type

Public

Founded year

2018

Operating status

Ipo

Headcount range

101–250 employees

Short description

Alebund Pharmaceuticals is a Shanghai-based clinical-stage biopharmaceutical company developing innovative therapies for chronic kidney disease, with a pipeline of eight products spanning hyperphosphatemia, renal anemia, and CKD progression indications.

Ownership category

akta.pro rank

Product category

Renal Disease Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)

Keywords

• Renal disease therapeutics
• Phosphate binder drugs
• Biopharmaceutical pipeline
• Chronic kidney disease
• Nephrology pharmaceuticals

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue from commercialized products including Mircera (methoxy polyethylene glycol-epoetin beta) for renal anemia, which has been included in China's National Reimbursement Drug List (NRDL). The company has established a commercial network covering major cities and hundreds of hospitals nationwide.
2. Licensing and Milestone Payments: Revenue from out-licensing arrangements including the AP306 licensing agreement with R1 Therapeutics, which includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales outside Greater China.
3. Future Product Revenue: Expected revenue from pipeline products including AP301 (hyperphosphatemia) and AP306 upon regulatory approvals. The company plans to submit AP301 NDA in China based on completed Phase III trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Alebund Pharmaceuticals develops and commercializes innovative drug therapies for the treatment of chronic kidney disease (CKD) and related complications. The company sells Mircera for renal anemia in China through NRDL channels and is advancing a pipeline of clinical-stage candidates including AP301 (a fiber-iron-based phosphate binder for hyperphosphatemia) and AP306 (a first-in-class pan-phosphate transporter inhibitor), supported by self-built GMP manufacturing in Yangzhou and an in-house hospital-focused sales team.

Product overview

Alebund Pharmaceuticals is an integrated biopharmaceutical company focused on kidney disease, with a diversified pipeline of 8 products covering the full spectrum of CKD: 1 commercialized product (Mircera® for renal anemia) and 7 pipeline candidates including 3 in clinical stage. The pipeline addresses both dialysis complications (hyperphosphatemia with AP301 and AP306) and disease progression (IgA nephropathy, diabetic kidney disease, FSGS, ADPKD, Alport syndrome). AP301 is a next-generation fiber-iron-based phosphate binder in global Phase III for hyperphosphatemia; AP306 is a first-in-class pan-phosphate transporter inhibitor in clinical development licensed to R1 Therapeutics for global development outside Greater China. The company operates an integrated platform spanning R&D, manufacturing (Yangzhou facility with 200 metric tons/year API capacity for AP301), and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• Mircera: Commercialized product for renal anemia, included in China's National Reimbursement Drug List
• AP301
• AP306

Products and services

• Mircera (methoxy polyethylene glycol-epoetin beta) A drug for renal anemia in chronic kidney disease patients, commercialized in China and included in the National Reimbursement Drug List (NRDL). Alebund distributes it through an in-house sales team covering major Chinese cities and hundreds of hospitals.
• AP301 (fiber-iron-based phosphate binder) A novel fiber-iron-based oral phosphate binder capsule for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Features high phosphate-binding capability, no need to chew before swallowing, minimal gastric fluid expansion, and no systemic absorption. Achieved 66.7% serum phosphate target attainment vs 58.6% for sevelamer carbonate at Week 52 in Phase III, with lower required daily dose (6.52 g/day vs 7.56 g/day).
• AP306 (EOS789) - Pan-sodium-dependent phosphate transporter inhibitor A first-in-class oral pan-sodium-dependent phosphate transporter inhibitor (NaPi-IIb, PiT-1, PiT-2) for treating hyperphosphatemia in CKD patients on dialysis. Works by blocking active intestinal phosphate transport rather than binding phosphate, representing a novel mechanism of action. Phase II showed serum phosphorus reduction of -2.51 mg/dL vs -1.08 mg/dL for sevelamer carbonate at significantly lower doses (288.30 mg/day vs 4650.99 mg/day).
• AP303 A drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) that has received FDA Orphan Drug Designation, providing accelerated regulatory pathway for the treatment of this genetic kidney disease.

Quantifiable outcome

• AP301 Phase III: 66.7% serum phosphate target attainment rate vs 58.6% for sevelamer carbonate at Week 52
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and strategic.

• R1 TherapeuticscoreStrategic or Co-development Partner · 17 March 2026Alebund granted R1 Therapeutics exclusive license to develop, manufacture, and commercialize AP306 outside Greater China. The collaboration includes potential milestone payments of up to low triple-digit millions of USD and tiered royalties in low double-digit percentage range on net sales. Alebund holds substantial equity interest in R1 with anti-dilution protection. R1 launched with $77.5M Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. Companies will jointly advance global Phase 2b MRCT in U.S. and China.
• Chugai Pharmaceutical (中外制药)coreTechnology or Integration · 1 January 2021Licensing agreement for AP306 (EOS789), a sodium-dependent phosphate transporter pan-inhibitor originally discovered by Chugai. Alebund completed Phase II clinical studies and has fully exercised options, now holding exclusive global development and commercialization rights for AP306.
• RochestrategicStrategic or Co-development PartnerStrategic collaboration for innovative therapies development. Alebund has commercialized Mircera (methoxy polyethylene glycol-epoetin beta), originally from Roche, which has been included in China's NRDL.
• Peking University First HospitalstrategicStrategic or Co-development PartnerCollaboration on kidney disease research. Alebund and Peking University First Hospital jointly established a kidney disease research center. Alebund also participated in a national key R&D program on diagnostic and monitoring technologies for immune kidney diseases.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• FibroGen: FibroGen developed roxadustat for anemia in CKD patients, directly competing with Alebund's Mircera franchise in the renal anemia space. Both companies pursue innovative approaches to anemia management in dialysis-dependent CKD patients and have experience commercializing renal products globally.
• Travere Therapeutics: Travere Therapeutics is a US biopharmaceutical company developing treatments for rare kidney diseases, including sparsentan for IgA nephropathy and FSGS—indications that overlap directly with Alebund's disease-modifying CKD pipeline. Both companies target the same nephrology specialty prescriber base with novel mechanisms.
• Akebia Therapeutics: Akebia Therapeutics develops therapeutics for kidney disease, with vadadustat for anemia due to CKD—a direct overlap with Alebund's Mircera commercial franchise. Both companies address the same dialysis/CKD patient population with anemia-focused and broader renal products.
• Everest Medicines: Everest Medicines is an Asia-focused biopharmaceutical company with renal franchises including Nefecon (budesonide) for IgA nephropathy. Like Alebund, Everest combines in-licensed Western assets with China/Asia commercialization infrastructure and pursues nephrology specialty indications.
• Ardelyx: Ardelyx is a US specialty biopharmaceutical company focused on renal and cardio-renal diseases, with Xphozah (tenapanor) approved for hyperphosphatemia in CKD patients on dialysis. It directly competes with Alebund's AP301 and AP306 in the same indication, patient population, and prescriber channel.
• Vera Therapeutics: Vera Therapeutics is a clinical-stage biotech developing atacicept for IgA nephropathy, a key indication in Alebund's disease-modifying CKD pipeline. Both companies target nephrology specialty physicians with novel biologics addressing immune-mediated kidney diseases.

Broad incumbents

• Vertex Pharmaceuticals: Vertex Pharmaceuticals has expanded into rare renal diseases through its APOL1-mediated kidney disease program (inaxaplin), positioning itself in the same nephrology specialty market Alebund targets with its CKD pipeline. While broader in therapeutic focus, Vertex is a credible competitor in nephrology innovation.
• Otsuka Pharmaceutical: Otsuka Pharmaceutical holds tolvaptan for ADPKD (Samsca/Jinarc), the only approved therapy for an indication in Alebund's early-stage pipeline (AP303 for ADPKD). Otsuka is a broad incumbent with established nephrology infrastructure that overlaps with multiple Alebund pipeline assets.
• CSL Vifor: CSL Vifor (formerly Vifor Pharma) is the global market leader in iron deficiency and nephrology pharmaceuticals, with established phosphate binder franchises (e.g., Velphoro). It represents a broad incumbent competitor across Alebund's dialysis-complication and renal anemia therapeutic areas.

Emerging players

• Cara Therapeutics: Cara Therapeutics developed difelikefalin (Korsuva) for chronic kidney disease-associated pruritus in dialysis patients—a related renal complication indication. While not a direct competitor in hyperphosphatemia or anemia, Cara addresses the same dialysis patient population with a novel mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alebund-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alebund Pharmaceuticals